Delcath Systems Inc (DCTH)vsDexCom Inc (DXCM)
DCTH
Delcath Systems Inc
$16.39
-0.06%
HEALTHCARE · Cap: $585.02M
DXCM
DexCom Inc
$89.29
+0.37%
HEALTHCARE · Cap: $33.69B
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 5108% more annual revenue ($4.97B vs $95.42M). DXCM leads profitability with a 20.1% profit margin vs 0.6%. DCTH appears more attractively valued with a PEG of 1.60. DXCM earns a higher WallStSmart Score of 72/100 (B).
DCTH
Hold41
out of 100
Grade: D
DXCM
Strong Buy72
out of 100
Grade: B
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 20.6% year-over-year
Every $100 of equity generates 38 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
Areas to Watch
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.4% — below average capital efficiency
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 12.8x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : DCTH
The strongest argument for DCTH centers on Debt/Equity, Revenue Growth. Revenue growth of 20.6% demonstrates continued momentum.
Bull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bear Case : DCTH
The primary concerns for DCTH are PEG Ratio, EPS Growth, Market Cap. A P/E of 1686.0x leaves little room for execution misses. Thin 0.6% margins leave little buffer for downturns.
Bear Case : DXCM
The primary concerns for DXCM are PEG Ratio, P/E Ratio, Price/Book.
Key Dynamics to Monitor
DCTH profiles as a growth stock while DXCM is a mature play — different risk/reward profiles.
DXCM carries more volatility with a beta of 1.41 — expect wider price swings.
DCTH is growing revenue faster at 20.6% — sustainability is the question.
DXCM generates stronger free cash flow (185M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (72/100 vs 41/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Delcath Systems Inc
HEALTHCARE · MEDICAL DEVICES · USA
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company is headquartered in New York, New York.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?